COVID-19: nirmatrelvir/ritonavir reduces the risk of a severe course in patients at risk

4 October 2022 - However, due to contra-indications and interactions, the combination of active ingredients is not suitable for all patients ...

Read more →

IQWiG publishes a new version of its general methods

5 November 2020 - New features include the investigation of volume-outcome relationships and different mean observation times in clinical studies. ...

Read more →

Mandatory or voluntary? A sticking point for European HTA

10 January 2019 - The long road to unified European Health Technology Assessment is continuing.  ...

Read more →